Henderson Jeffrey William's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Feb 4, 2025
- Accession no.
- 0001415889-25-003006
- Filed
- Feb 4, 2025
- Trade date
- Feb 3, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $281.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Henderson Jeffrey WilliamCIK 0001324015 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | Common Stock | SSaleDisposed | −1,100 | $55.94 | −$61,534 | 42,511 | Direct | |
| Feb 3, 2025 | Common Stock | SSaleDisposed | −3,900 | $56.41 | −$219,999 | 38,611 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.